Zaash Labs publishes analyst led market intelligence reports on newly approved therapies. Each report delivers a revenue forecast, a competitive assessment, a geographic adoption outlook and a regulatory risk review, with every figure sourced and every assumption disclosed.
Investment committees, business development teams and market access leads act in the days that follow an approval. Conventional syndicated research is comprehensive, but it is often priced and paced for a different purpose.
| Conventional syndicated report | Zaash Labs report | |
|---|---|---|
| Price | USD 3,000 to 5,000 or more | USD 650, with internal team sharing included |
| Length | 150 to 200 pages | 25 pages in a consistent structure |
| Timing | Weeks or months after the event | Within five business days of approval |
| Forecast transparency | Outputs often presented without the underlying model | Full assumptions, patient funnel and sensitivity analysis printed |
Every report follows the same eight sections, so readers know exactly where to find each answer.
The investment and commercial verdict in a single page.
Mechanism of action, indication, pivotal trial design, efficacy and safety against the standard of care.
Eligible population, pricing and uptake modelled to peak sales, with base, upside and downside cases.
Comparison against approved therapies and the Phase II and III pipeline, with a market share outlook.
United States, EU5, Japan and China: launch sequencing, pricing and reimbursement outlook.
Label restrictions, health technology assessment hurdles and safety considerations.
Dedicated guidance for investors, business development and market access teams.
Sources, methodology and model assumptions, so every figure can be verified.
Each report is led and verified by an analyst with clinical training in pharmacy and experience across pharmaceuticals, medical devices and clinical AI. The process is the same for every report.
FDA and EMA labels, pivotal trial records on ClinicalTrials.gov, company filings and disclosures, peer reviewed epidemiology and published HTA decisions.
A bottom up patient funnel, net price assumptions and an uptake curve benchmarked against comparable launches.
Trial results are interpreted in their clinical context, including endpoints missed, safety signals and real prescribing behaviour.
Every figure is traced back to its source, and all assumptions are printed in the appendix for the reader to test.
AI assists with our research and drafting. What it cannot provide on its own is verified sources, sound clinical judgement and accountability. Fully automated market reports are now widespread and inexpensive, but they are difficult to rely on for decisions with real money attached. The difference shows in the detail.
| Typical fully automated report | Zaash Labs report | |
|---|---|---|
| Sources | Unclear or unverifiable, and sometimes invented citations | Every source named and cited in the appendix |
| Numbers | Figures that read plausibly but cannot be traced or reproduced | A transparent model you can audit line by line |
| Clinical judgement | Restates press releases and company positioning | Interprets missed endpoints, safety signals and real world use |
| Currency | Limited by training data, often months out of date | Researched from documents published in the days after approval |
| Accountability | No named author and no one to question | A named analyst who answers your questions about the work |
Review the free executive summary first, then purchase the full report.
Executive verdict, pivotal trial comparison, revenue forecast to 2031, competitive landscape, geographic adoption, six regulatory and access risks, and implications by role.
PDF delivered by email · Internal team sharing included
We send a secure payment link or an invoice for your finance team.
Two pages covering the verdict, the headline forecast and the structure of the full report. You will also receive the executive summary of each new report when it is published. You can unsubscribe at any time.
Our target is publication within five business days of a major approval or Phase III readout.
FDA and EMA labels, ClinicalTrials.gov, company filings and disclosures, peer reviewed epidemiology and published HTA decisions. All sources are listed in each report's appendix. We do not rely on undisclosed datasets.
Yes, as an assistant. AI helps with research and drafting. Every figure, assumption and conclusion is then checked against cited sources by a pharmacist trained analyst, and the analyst signs off on the final report. You can question any number and we will show you where it came from.
Yes. A single purchase covers internal sharing across your team.
Submit a purchase request and we will send a secure payment link or an invoice for your finance team, whichever you prefer.
Yes. Custom reports are available on request. Use the form below to tell us which product and indication you need.
No. Our reports are market research to support business decisions.
Tell us which report you would like, or which product you want covered next. We respond within one business day.
About Zaash Labs. Zaash Labs is a healthcare market research firm focused on one moment: when a Phase III success turns a therapy into a market. The firm was founded by Priyank Rangnekar, a pharmacist by training with more than eight years of experience across pharmaceuticals, medical devices and clinical AI.